Heart Failure Connect
  • Saved
Efficacy of catheter ablation for atrial fibrillation in heart failure: a meta-analysis of randomized controlled trials

Efficacy of catheter ablation for atrial fibrillation in heart failure: a meta-analysis of randomized controlled trials

Source : https://pubmed.ncbi.nlm.nih.gov/38661235/

The study aims to evaluate whether rhythm control by catheter ablation is superior to medical therapy for the patients with atrial fibrillation (AF) and heart failure (HF). The literatures were...

Catheter ablation significantly improves survival, reduces heart failure re-hospitalization, enhances left ventricular function, and quality of life in atrial fibrillation patients with heart failure compared to medical therapy.

  • Saved
Systematic review and meta-analysis of stroke and thromboembolism risk in atrial fibrillation with preserved vs. reduced ejection fraction heart failure - PubMed

Systematic review and meta-analysis of stroke and thromboembolism risk in atrial fibrillation with preserved vs. reduced ejection fraction heart failure - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39289613/

The findings suggest that there is no significantly different risk of stroke and systemic thromboembolism in cases of AF with associated HFpEF or HFrEF. The finding does not support integration...

This study found no significant difference in stroke and thromboembolism risk between atrial fibrillation patients with preserved or reduced ejection fraction, suggesting ejection fraction shouldn't factor into stroke risk assessments.

  • Saved
A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial - PubMed

A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36748670/

The differences between the groups for the majority of clinical parameters compared were minimal, except for younger age, higher body mass index and serum creatinine level and lower left ventricular...

A study compared heart failure patients in the Moravian Midlands Registry with Paradigm-HF trial participants, revealing younger age, higher BMI, lower ejection fraction, and more device therapies in the MMR cohort.

  • Saved
A patient with dyspnea on exertion, orthopnea, and cough

A 68-year-old woman, Mrs. M presents with a history of hypertension and paroxysmal atrial fibrillation. She complains of fatigue, dry cough, and shortness of breath while walking her dog or lying down flat. She is not experiencing chest pain or lightheadedness. She drinks alcohol rarely, has never smoked tobacco, and does not engage in recreational drug use.

She is taking the following medications:

  • Diuretic
  • Beta-blocker
  • Angiotensin-converting enzyme inhibitor
  • Anticoagulant

Her physical exam reveals:

  • Body mass index 29 kg/m2
  • Blood pressure 128/74 mm Hg
  • Heart rate 88 beats/minute; regular rhythm; no murmur
  • Bilateral rales
  • Bilateral pedal edema

Her N-terminal pro B-type natriuretic peptide score is 990 pg/mL. All other laboratory tests are within normal limits. Electrocardiography shows normal sinus rhythm. On echocardiography, she has a left ventricular (LV) ejection fraction of 55%, LV wall thickness of 14 mm, and an average E/e’ ratio of 16.

Based on these results, you decide to initiate guideline-directed medical therapy for heart failure with preserved ejection fraction (HFpEF) and assess Mrs. M for symptomatic improvement.

Based on HFpEF guidelines, which class(es) of medication would help reduce Mrs. M’s risk of hospitalization for heart failure and cardiovascular death, and why?

  • 1yr
    She is in mild CHF so initial approach is to decongest. For the long term, treatment of her HFpEF with SGLT2i, MRA, and ARNI will help decrease risk of hospitalization Show More
  • 2yr
    For this patient with HFPEF would add SGLT2I - Jardiance or Farxiga. As well her diuretic therapy should include MRA like spironolactone.

Show More Comments

  • Saved
Role of dietary sodium restriction in chronic heart failure: systematic review and meta-analysis - PubMed

Role of dietary sodium restriction in chronic heart failure: systematic review and meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37389661/

In a meta-analysis, sodium restriction in CHF patients worsened the prognosis in terms of a composite of mortality and hospitalizations and did not influence all-cause mortality and HF hospitalisation rate.

Dietary sodium restriction in chronic heart failure patients may worsen prognosis, increasing composite mortality and hospitalization risk without significantly affecting overall mortality or heart failure admissions.